Anti-tumor agent

Details Anti-tumor agent Anti-tumor agent

2011-01-04

2011-01-04

Huff, Sheela J (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

07863243

ABSTRACT:
The present invention provides a new anti-tumor agent containing adiponectin as an active ingredient, particularly, an anti-tumor agent capable of inhibiting carcinogenesis in the liver, use of adiponectin as an anti-tumor agent, and a prophylactic or therapeutic method against a tumor using adiponectin. The administration form may be either oral administration, e.g., by tablets or parenteral administration, e.g., by injection; in the case of intravenous injection for inhibiting carcinogenesis in the liver, the dosage is 1 to 100 mg/kg/day per adult patient.

REFERENCES:
patent: 1 365 022 (2003-11-01), None
patent: 1 393 739 (2004-03-01), None
patent: 1 589 106 (2005-10-01), None
patent: 2000-256208 (2000-09-01), None
patent: 2002-515452 (2002-05-01), None
patent: 2002-517259 (2002-06-01), None
patent: 2002-363094 (2002-12-01), None
patent: 2003-527067 (2003-09-01), None
patent: 2004-331570 (2004-11-01), None
patent: 2004-345968 (2004-12-01), None
patent: WO 99/59618 (1999-11-01), None
patent: WO 99/59619 (1999-11-01), None
patent: WO 99/64629 (1999-12-01), None
patent: WO 02/061076 (2002-08-01), None
patent: WO 02/072149 (2002-09-01), None
patent: 03/062275 (2003-07-01), None
patent: 2004/063711 (2004-07-01), None
patent: WO 2004/061108 (2004-07-01), None
patent: WO 2005/031345 (2005-04-01), None
Skolnick et al. (Trends in Biotech., 18(1):34-39, 2000).
Matsuzawa, Accession No. 2005:43451, 2005 (abstract only).
Tamura et al Adiposcience (2005) 2(2): 122-127.
Translation of Tamura et al Adiposcience (2005) 2(2): 122-127.
Essell (J. NIH Res. 1995 7:46).
Spitler (Cancer Biotherapy, 1995, 10:1-3).
Boon (Adv. Can. Res. 1992 58:177-210.
Waki et al., “Impaired Multimerization of Human Adiponectin Mutants Associated with Diabetes,” Journal of Biological Chemistry, vol. 278, No. 41, pp. 40352-40363, 2003.
Pajvani et al., “Structure-Function Studies of the Adipocyte-secreted Hormone Acrp30/Adiponectin,” Journal of Biological Chemistry, vol. 278, No. 11, pp. 9073-9085, 2003.
Scherer et al., “A Novel Serum Protein Similar to Clq, Produced Exclusively in Adipocytes,” Journal of Biological Chemistry, vol. 270, No. 45, pp. 26746-26749, 1995.
Kamada et al., “Enhanced Carbon Tetrachloride-Induced Liver Fibrosis in Mice Lacking Adiponectin,” Gastroenterology vol. 125, pp. 1796-1807, 2003.
Maeda et al., “Diet-induced Insulin Resistance in Mice Lacking Adiponectin/ACRP30,” Nature Medicine, vol. 8, No. 7, 2002.
Nakae et al., “High Incidence of Hepatocellular Carcinomas Induced by a Choline Deficient L-Amino Acid Defined Diet in Rats,” Cancer Research 52, pp. 5042-4045, 1992.
Xu et al. “The Fat-derived Hormone Adiponectin Alleviates Alcoholic and Nonalcoholic Fatty Liver Diseases in Mice,” Journal of Clinical Investigation, vol. 112, No. 1, 2003.
Kamata, “P-129 Effects of Adiponectin in the Liver,” Kanzo (img id="CUSTOM-CHARACTER-00001" he="3.13mm" wi="5.25mm" file="US07863243-20110104-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?: Liver), vol. 44, No. Supplement 2, p.A420, 2003.
WIPO, PCT Notification Concerning Transmittal of International Preliminary Report on Patentability dated May 18, 2006 and accompanying PCT International Preliminary Report on Patentability.
Kazuhisa Maeda et al. “cDNA Cloning And Expression Of A Novel Adipose Specific Collegen-like Factor, apMI (Adipose Most Abundant Gene Transcript 1)”Biochemical and Biophysical Research Communications, No. 0587, 221, pp. 286-289, (1990).
Yukio Arita et al. “Paradoxical Decrease Of An Adipose-Specific Protein, Adiponectin, In Obesity”Biochemical and Biophysical Research Communications, No. 257, pp. 79-83.
Yuji Matsuzawa “Adiponectin: Identification, Physiology And Clinical Relevance In Metabolic And Vascular Disease”Atherosclerosis Supplements, No. 6, pp. 7-14 (2005).
International Search Report for international application No. PCT/JP2004/015900, mailed on Dec. 14, 2004.
Kawata, Y. et al., “Controlling Effect of Adiponectin for a Liver Fat Deposition and a Liver Cancer Incidence”,Acta Hepatolobica Japonica, 45(1):A41, WS-11, Apr. 2004.
Shimamora, I. et al.,The Journal of the Japanese Society of Internal Medicine, 92(4), Apr. 2003, pp. 609-615.
Yoshiro Kamata, et al, “Effects of Adiponectin in the Liver”Liver, Sep. 30, 2003, vol. 44, Supplement 2, A420, P-129 (with English Translation).
Yoshiro Kamata, et al, “Suppression Effect of the Adipocyte Specific Protein Adiponectin (AN) on Liver Fibrosis”Liver, Sep. 30, 2002, vol. 43, Supplement 2, A268, S5-3 (with English Translation).
Norio Hayashi, Hepatology, Nihon-Yakuji-Shinpou, Feb. 8, 2003, vol. 4111, p. 14-20 (with English Translation).
Yasuo Miyoshi, et al, Serum Adiponectin Levels and Breast Cancer Risk,Japanese Cancer Association Assembly Abstract, Aug. 25, 2003, p. 88 assembly 1051-PA (with English Translation).
Kenta Motomura, “Relation of Diabetes and Obesity to Non-B, Non-C Hepatocellular Carcinoma”,The 7th Assembly of Japan Society of Hepatology Abstract, Sep. 30, 2003, A389, P-7 (with English Translation).

Affiliated with

Also associated with

Rating

Anti-tumor agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-tumor agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-tumor agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2680664